Remove Biomarkers Remove Kidney Disease Remove Outcomes
article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research in Chronic Kidney Disease at ACC.25

DAIC

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25

article thumbnail

Hyperuricaemia elevates risk of short-term readmission and mortality in patients with heart failure

Open Heart

Results Baseline characteristics revealed significant differences between NUA and HUA groups, with the latter exhibiting a higher prevalence of males, chronic kidney disease (CKD) and elevated levels of various biomarkers. in the NUA group.

article thumbnail

Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review

Circulation

Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascular risk factors. Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025.

article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research

DAIC

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25

article thumbnail

Targeting pharmacotherapies for inflammatory and cardiorenal endpoints in kidney disease

Journal of Cardiovascular Pharmacology

Understanding and addressing the dysregulated immune system is a promising approach to modifying cardiorenal outcomes in people with CKD. Understanding and addressing the dysregulated immune system is a promising approach to modifying cardiorenal outcomes in people with CKD.

article thumbnail

Predictors of worse outcome after postponing non-emergency cardiac interventions during the COVID-19 pandemic

Open Heart

This study aimed to identify predictors of worse clinical outcome after deferral of non-emergency cardiovascular interventions. to 5.12; p=0.049), chronic kidney disease (HR 1.89; 95% CI 1.03 to 3.49; p=0.041) as well as severe valvular heart disease (HR 3.08; 95% CI 1.68 Arterial hypertension (HR 2.27; 95% CI 1.00

article thumbnail

Effects of empaglifozin on collagen biomarkers in patients with Heart Failure. Findings from the EMPEROR trials

European Journal of Heart Failure

A mixed model repeated measurements model (MMRM) was used to evaluate the effect of empagliflozin vs. placebo on the analysed biomarkers. On the other hand, PRO-C3, C1M, and C3M were not associated with worse HF severity or study outcomes.